Orchard Therapeutics Up 11% as FDA Gives Priority Review to Biologics License Application
By Sabela Ojea
Shares of Orchard Therapeutics on Monday climbed after the
company said the U.S. Food and Drug Administration accepted the
filing of its biologics license application to treat a rare disease
called metachromatic leukodystrophy under priority review.
At 14:18 pm E.T., shares were up 11% at $5.75. The stock has
jumped 55% since the year started and increased 23% in the past 12
The gene therapy biotechnology company said the FDA's approval
relates to its OTL-200 treatment, which previously received both
rare pediatric disease and regenerative medicine advanced therapy
designations from the FDA.
"We are working diligently in parallel to prepare for a
potential launch in 2024 and ensure OTL-200 will be available to
patients in the U.S. as quickly as possible," Chief Executive Bobby
Metachromatic leukodystrophy is a rare hereditary disease that
damages the central nervous system.
Write to Sabela Ojea at firstname.lastname@example.org; @sabelaojeaguix
(END) Dow Jones Newswires
September 18, 2023 14:59 ET (18:59 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.